SUNWELS Co.,Ltd. (JP:9229)
:9229
Top Page
SUNWELS Co.,Ltd.
(9229)
Select Model
Select Model
Rating:51Neutral
Price Target:
¥271.00
▼(-20.99% Downside)
Action:ReiteratedDate:03/27/26
The score is primarily driven by mixed financial performance: strong top-line growth but pressured profitability, high leverage, and negative free cash flow. Technicals add a modest drag with the stock below key longer-term moving averages and a negative MACD, while valuation is constrained by loss-making results and the absence of a dividend yield.
Positive Factors
Sustained Revenue Growth
Consistent top-line expansion from 2020–2025 indicates enduring demand for SUNWELS’ care services and supports scale advantages. Over a multi-month horizon, growing revenue provides a base to improve unit economics, invest in capacity, and leverage fixed-cost absorption to help stabilize margins.
Negative Factors
High Financial Leverage
Elevated debt-to-equity increases fixed interest costs and reduces financial flexibility. Over the medium term this constrains investment, magnifies earnings volatility from operational stress, and raises refinancing risk if cash flows or credit conditions deteriorate.
Read all positive and negative factors
Positive Factors
Negative Factors
Sustained Revenue Growth
Consistent top-line expansion from 2020–2025 indicates enduring demand for SUNWELS’ care services and supports scale advantages. Over a multi-month horizon, growing revenue provides a base to improve unit economics, invest in capacity, and leverage fixed-cost absorption to help stabilize margins.
Read all positive factors
SUNWELS Co.,Ltd. (9229) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥9.26B
Dividend YieldN/A
Average Volume (3M)115.88K
Price to Earnings (P/E)―
Beta (1Y)1.09
Revenue Growth10.09%
EPS Growth-340.83%
CountryJP
Employees2,435
SectorHealthcare
Sector Strength45
IndustryMedical - Care Facilities
Share Statistics
EPS (TTM)-16.60
Shares Outstanding35,220,000
10 Day Avg. Volume157,720
30 Day Avg. Volume115,876
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)2.13
Price to Sales (P/S)0.69
P/FCF Ratio-7.88
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-27.7
Revenue Forecast (FY)¥32.00B
SUNWELS Co.,Ltd. Business Overview & Revenue Model
Company Description
Sunwels Co.,Ltd. operates nursing care business centered on PD house. It operates homes for the elderly that specializes in Parkinson disease, as well as a Kaatsu training gym; provides day care, in-home care support, care plan, and home remodelin...
How the Company Makes Money
null...
SUNWELS Co.,Ltd. Financial Statement Overview
Summary
Income Statement
55
Neutral
Balance Sheet
50
Neutral
Cash Flow
60
Neutral
| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 26.86B | 26.50B | 20.11B | 13.24B | 8.17B | 5.40B |
| Gross Profit | 3.99B | 4.89B | 5.13B | 3.24B | 1.60B | 1.37B |
| EBITDA | 1.54B | 2.50B | 3.09B | 1.45B | 557.48M | 503.99M |
| Net Income | -1.77B | -925.00M | 802.00M | 303.60M | 10.65M | 241.42M |
Balance Sheet | ||||||
| Total Assets | 42.22B | 39.44B | 31.74B | 19.30B | 9.10B | 4.88B |
| Cash, Cash Equivalents and Short-Term Investments | 3.62B | 5.64B | 3.31B | 2.61B | 814.76M | 496.36M |
| Total Debt | 26.35B | 22.49B | 20.11B | 11.20B | 6.60B | 3.03B |
| Total Liabilities | 34.32B | 30.82B | 26.54B | 14.69B | 8.52B | 4.19B |
| Stockholders Equity | 7.89B | 8.62B | 5.20B | 4.61B | 580.80M | 693.47M |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | -2.32B | -2.93B | -740.86M | -73.95M | -386.44M |
| Operating Cash Flow | 0.00 | 1.88B | 2.56B | 1.14B | 378.19M | 201.03M |
| Investing Cash Flow | 0.00 | -4.40B | -5.66B | -2.04B | -633.05M | -648.06M |
| Financing Cash Flow | 0.00 | 4.84B | 3.80B | 2.70B | 573.26M | 489.42M |
SUNWELS Co.,Ltd. Technical Analysis
Negative
343.00
Price Trends
280.78
Negative
342.29
Negative
509.15
Negative
Market Momentum
-7.58
Negative
44.30
Neutral
27.59
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:9229, the sentiment is Negative. The current price of 343 is above the 20-day moving average (MA) of 250.45, above the 50-day MA of 280.78, and below the 200-day MA of 509.15, indicating a bearish trend. The MACD of -7.58 indicates Negative momentum. The RSI at 44.30 is Neutral, neither overbought nor oversold. The STOCH value of 27.59 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:9229.
SUNWELS Co.,Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
81 Outperform | ¥2.92B | 4.69 | ― | 2.82% | 4.82% | 9.78% | |
74 Outperform | ¥2.83B | 27.02 | ― | 2.56% | -3.06% | -38.56% | |
68 Neutral | ¥105.73B | 16.02 | ― | 2.47% | 1.86% | 1370.48% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | ¥9.26B | -5.17 | ― | ― | 10.09% | -340.83% | |
51 Neutral | ¥5.88B | 23.20 | ― | 4.07% | 6.08% | 38.00% | |
45 Neutral | ¥6.66B | 33.86 | ― | 1.41% | 18.03% | -11.68% |
* Healthcare Sector Average
JP:9229
SUNWELS Co.,Ltd.
263.00
-242.00
-47.92%
JP:2373
Care Twentyone Corporation
437.00
75.63
20.93%
JP:2425
Care Service Co., Ltd.
747.00
33.49
4.69%
JP:6197
Solasto Corp.
1,116.00
709.15
174.30%
JP:7061
Japan Hospice Holdings Inc.
790.00
-524.18
-39.89%
JP:9220
FB CARE SERVICE CO.,LTD.
1,198.00
332.90
38.48%
SUNWELS Co.,Ltd. Corporate Events
Sunwels Highlights Q3 FY2026 Progress in Specialized Healthcare and Caregiving
Feb 13, 2026
Sunwels Co., Ltd. reported highlights for the third quarter of its fiscal year ending March 2026, emphasizing its strategic focus on specialized healthcare and caregiving services. The company underscored initiatives such as the ‘PD House...
SUNWELS slips into loss despite higher sales, cuts equity ratio as full-year losses loom
Feb 13, 2026
SUNWELS Co., Ltd. reported non-consolidated net sales of ¥20.73 billion for the nine months ended December 31, 2025, a modest 2.2% increase year on year, but swung to an operating loss of ¥1.19 billion and a net loss of ¥2.06 billio...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.